雙鷺藥業(002038.SZ)業績快報:2020年淨利降26.78%至3.56億元
格隆匯 2 月 26日丨雙鷺藥業(002038.SZ)披露2020年度業績快報,報吿期內,公司實現營業收入11.19億元,同比減少44.85%,實現營業利潤4.0億元,同比下降28.71%;利潤總額4.0億元,同比下降28.71%;實現歸屬於上市公司股東的淨利潤3.56億元,同比下降26.78%;基本每股收益0.3469元。
營業收入變動主要系受疫情和主要產品複合輔酶、胸腺五肽均從地方醫保目錄調出,銷售訂單減少,導致收入減少所致。業績變動主要系報吿期內主要產品收入減少,研發、管理等費用增加,以及投資收益增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.